Cancer is a disease characterized by genomic instability. Comparative genomic hybridization (CGH) is a technique designed for detecting segmental genomic alterations. Recent advances in array-based CGH technology have enabled examination of chromosomal regions in unprecedented detail, revolutionizing our understanding of tumour genomes. A number of array-based technologies have been developed, aiming to improve the resolution of CGH, enabling researchers to refine and define regions in the genome that may be causal to cancer, and facilitating gene discovery at a rapid rate. This article reviews the various array CGH platforms and their use in the study of cancer genomes. In addition, the need for high-resolution analysis is discussed as well as the importance of studying early-stage disease to discover genetic alterations that may be causal to cancer progression and aetiology.
Introduction
Genetic alteration is a hallmark of cancer. Amplification of oncogenes and deletion of tumour suppressors are common events in cancer progression. Identifying segmental genomic alterations (SeGAs) and the genes they contain will yield molecular targets for diagnostics and therapy. Comparative genomic hybridization (CGH) is a technique designed to identify copynumber changes (Kallioniemi et al. 1992) . In principle, a normal and a pathological DNA sample are differentially labelled and compared by competitive hybridization against a normal metaphase chromosome spread detecting gains and losses based on changes in signal ratios (Forozan et al. 1997) . Array-based CGH greatly improves the resolution of the technique by substituting the hybridization target, the metaphase chromosome spread, with genomic segments spotted in an array format (Figure 1 ). This article reviews the various array CGH platforms and their application to describe cancer genomes.
Array-based CGH analysis of chromosomal regions altered in cancer
Microarray analysis of genomic copy number changes has led to the development of new, and the adaptation of existing, microarray platforms ( Figure 2 ). Array CGH, also called matrix CGH, was initially used to identify segmental alterations in specific chromosomal regions associated with disease. Solinas-Toldo et al. (1997) assessed the use of microarray technology to detect chromosomal imbalances as a way to improve on the resolution of CGH by constructing an array which contained large-insert clones (LIC) spanning 13q14 and other regions. The analysis of a panel of cell line and tumour genomes demonstrated that this approach improved the resolution of conventional CGH from 10 Mb to the detection of SeGAs of 75-130 kb in size.
Since this study, a number of regional arrays have been developed to investigate speci¢c genomic 'hotspots' in a variety of diseases. Target clones may span a region often associated with copy number changes in neoplasms or a region harbouring a known gene involved in tumourigenesis in one or more cancers. For example, Garnis and colleagues developed an array covering the *52-Mb region from 8q21^24 to discover a novel region commonly ampli¢ed in pre-invasive oral and lung cancer (Garnis et al. 2004c (Garnis et al. , 2004d . Importantly, the amplicon was distinct from the neighbouring MYC oncogene and contained a gene whose overexpression appeared to be an early event in cancer progression. Due to the limited resolution of conventional metaphase CGH, previous studies have routinely attributed 8q alterations to the ampli¢cation of the MYC oncogene. This example illustrates the need for and utility of high-resolution genomic microarrays.
Disease-speci¢c arrays have been developed to survey chromosomal regions commonly altered in chronic lymphocytic leukaemia, mantle cell lymphoma, oral, pancreatic, lung and other cancers, and will be further discussed below (Albertson et al. 2000 , Massion et al. 2002 , Garnis et al. 2004b , Holzmann et al. 2004 ).
Chromosome-speci¢c arrays
The next generation of genomic microarrays examined a specific chromosome or chromosome arm. For example, a chromosome 20 array containing 22 cosmid, P1 phage artificial chromosome (PAC) and bacterial artificial chromosome (BAC) clones as interval markers covering chromosome 20 at 3 Mb resolution (Figure 3; Pinkel. et al. 1998) . Applying this array to study breast cancer, SeGAs at multiple regions were detected on this chromosome suggesting that higherdensity arrays would probably reveal more complex chromosomal alterations in cancer genomes than previously appreciated (Pinkel et al. 1998) . In another example, Buckley et al. (2002) created a comprehensive array for the smallest autosome, chromosome 22. Interestingly, of the 480 target clones spotted, 476 were LICs and four were pools of repeat-free PCR-amplified genomic DNA. The PCR-based probes were used as a proof-of-principle example to show that areas of the genome that are repeat-rich or contain duplications -areas that can give unreliable copynumber data using clone-based assays -can be accurately assessed at a high resolution. This labour-intensive PCR-based method is well suited for regional array construction or to complement higher-coverage arrays on repeat-rich regions (Mantripragada et al. 2004) . Recently, a number of BAC clone-based contiguous arm arrays have been developed. These arrays provide complete coverage of the 1p, 3p and 5p arms, which are frequently altered in a variety of cancers (Garnis et al. 2003 . These arrays have Figure 1 . General principles of array comparative genomic hybridization. (a) Normal and tumour DNA samples are isolated and used to create fluorescently labelled probes, commonly with cyanine 3 (Cy3; green) and cyanine 5 (Cy5; red) dyes. The probes are pooled and competitively cohybridized to a glass slide spotted with a known array of mapped genomic clones. The arrays are analysed with a microarray scanner, producing an image that is used to assess the log2 ratios of the Cy5 to Cy3 intensities for each clone. proven instrumental in fine-mapping SeGAs in oral squamous cell carcinoma, small-cell and non-small-cell lung carcinoma.
Genome-wide approaches
Although CGH studies using regional and chromosomal microarrays have yielded a great deal of information, these studies are naturally biased to specific areas of the genome and require a priori knowledge of regions of interest. To overcome regional bias, genome-wide arrays were employed (Figure 2 ). In a pioneer study, Pollack et al. (1999) used a cDNA microarray representing 3195 unique cDNA target clones distributed throughout the genome. This study constituted the first array-based genome-wide profiling of human cancer genomes, defining known regions of alteration such as the amplicon containing the well-characterized ERBB2 oncogene in breast cancer. The use of cDNA arrays for genomewide array CGH was a significant advance in the field of cancer genomics. In addition, since the platform was originally designed for gene expression studies, linking genomic data to expression data is greatly facilitated. However, the low signal-to-noise ratio and variable signal intensities are major concerns about using cDNA clones as targets for detecting copy-number alterations. This results from the smaller target size of cDNA clones compared with large-insert genomic clones due to a lack of intronic regions and the varying length of the cDNA target. The technique is effective at resolving high-level SeGAs; however, in order to reliably detect singlecopy changes, a moving-average of clone intensities must be calculated, thereby reducing the resolving power of the arrays. Moreover, larger quantities (micrograms) of sample genomic DNA are required in order to generate a robust signal, thus limiting the utility of cDNA array CGH (Pollack et al. 1999) . As LICs provide stronger signal intensities, BAC arrays were constructed for genome-wide SeGA profiling. Using 2460 BAC and P1 clones, Snijders et al. (2001) created an array with an average marker interval of 1.4 Mb, capable of detecting high-and low-level genomic alterations, substantiating the utility of LIC-based genomic microarrays. Since this initial study, a number of other megabase-interval arrays have been published and are widely used in cancer research (Fiegler et al. 2003a .
Oligonucleotide arrays are also used in copynumber detection (Figure 2 ). For example, the A¡ymetrix p501 array, the Mapping 10 K array, and the XbaI mapping array 130, containing 8473, 11 555 and 10 043 target probes respectively, have been used in array CGH studies (Bignell et al. 2004 , Zhao et al. 2004 . These arrays contain 25-mer oligonucleotides originally designed to assess human single-nucleotide polymorphisms (SNPs). Although such arrays o¡er an opportunity for integrating LOH data based on SNP analysis, the inherent problem of cross hybridization of oligonucleotide targets to multiple genomic loci invokes the need for complexity reduction of the sample genomic DNA. In order to increase signalto-noise ratios, the whole-genome sampling assay (WGSA) was developed to greatly reduce the genomic complexity of the sample probes by about 98% to improve hybridization kinetics (Kennedy et al. 2003) . Brie£y, this is achieved by linkermediated PCR of XbaI (or EcoRI or BglII)-digested genomic sample DNA^only short restriction fragments would be ampli¢ed (Figure 4) .
Hybridization of complexity-reduced probes to SNP arrays is able to detect high-level copynumber changes; however, since the resolution of the method is dependent on the inconsistent Figure 3 . Comparison of the genome-target probe densities used to spot microarrays. The resolution of a marker-based microarray is dependent on the distances or gaps between clones -for a hypothetical array with gap sizes of '0', the resolution of the array is limited to the size of the clone. For a tiling-based array, the resolution is dependent on the amount of overlap for each clone, increasing the resolution beyond clone size. SNP-density on the array, over a ¢fth of the chromosomes measured were inconsistent with the SeGAs detected by BAC-array CGH due to poor SNP representation (Bignell et al. 2004) . In addition, the data generated by the SNP-arrays showed high variability, probably due to the requirement of PCR ampli¢cation of genomic sample DNA. This necessitated the use of a moving average to detect copy-number changes, further lowering the e¡ective resolution of the method (Bignell et al. 2004) . However, as more SNPs are characterized, this method will prove to be a powerful technique in the future (for example, by using a 100k SNP array; Matsuzaki et al. 2004 ). In addition, this method has the advantage of measuring allelic loss of heterozygosity (LOH) alongside copy-number changes using the same platform. Therefore, this technique can greatly improve our understanding of the complex genetic events that may be causal to carcinogenesis.
Similarly, the representative oligonucleotide microarray analysis (ROMA) method reduces the complexity of the genomic DNA sample to *2.5% of the genome via the BglII restriction enzyme and linker-mediated PCR ampli¢cation (Lucito et al. 2003) . Using an oligonucleotide microarray consisting of 85 000 target probes of 70-mers designed to detect the genomic 'representations' created by selective ampli¢cation of restriction fragments, ROMA aims to detect SeGAs at an average theoretical resolution of 30 kb assuming an even distribution of BglII sites of the human genome. The identi¢cation of submegabase copy-number alterations by this method in breast cancer cell lines and tumours illustrates the need for high-resolution analysis of cancer genomics.
Since ROMA and WGSA employ a genomereduction step requiring selective PCR ampli¢ca-tion of sample DNA, noise is introduced into the assay. Furthermore, the requirement of matched qualities and quantities as well as parallel processing of the sample and test genomes may preclude the use of reduction-based strategies from retrospective studies which rely on archival, formalin¢xed para⁄n-embedded material yielding DNA of varying amounts and qualities. In contrast to genomic reduction approaches, Brennan et al. (2004) have recently demonstrated that labelling of total genomic DNA can be used to detect single-copy alterations on an oligonucleotide array without a genomic reduction step. However, microgram quantities of starting material are required, which may limit the technique to large tumours and cell lines.
The marker-based genome-wide arrays mentioned thus far, albeit only representing up to 10^15% of the genome, have been instrumental in identifying large (typically greater than 1^2 Mb) variations in somatic genetic changes in tumours as well as in large scale copy number variations in the human population (Iafrate et al. 2004 , Sebat et al. 2004 .
Whole genome tiling path array CGH
In order to comprehensively assess the genome and to identify the focal genetic events occurring during carcinogenesis, a whole genome (as opposed to genome-wide only) approach must be employed (Figure 2) . Recently, Ishkanian and colleagues (2004) published the first submegabase resolution tiling-set (SMRT) array that contiguously covered the human genome in a tiling path manner ( Figure  3) . By using overlapping clones, the resolution of the array was increased beyond the size of a single BAC clone and gains and losses of regions as small as 40-80 kb are detectable.
A major advantage of using a tiling-path array is in identifying small (gene level) gains and losses, since marker-based genomic microarrays inherently have a large number of gaps due to the distance between target probes, reducing the likelihood of detecting novel microalterations. That is, the probability of missing a small genetic alteration is inversely proportional to the genome coverage or representation of the detection strategy ( Figure  5 ). The tiling path array o¡ers a much greater probability of detecting small-sized alterations (e.g. 40 kb) than marker-based genomic arrays. The even distribution of markers throughout the genome, as opposed to having a large number of small loci clustered in selected regions, is a key consideration in improving the resolution of genomic scanning strategies. The SMRT array, a tiling-path array, is composed of 32 433 clones spotted in triplicate over two microarray slides (Ishkanian et al. 2004) . Figure 6 shows a SMRT array CGH karyogram of a lung tumour genome displayed using SeeGH software (Chi et al. 2004) , highlighting the ability of whole genome tiling path arrays in identifying gains and losses as well as the boundaries of the alterations in a single experiment. The clones used have a high degree of overlap and loci redundancy (i.e. multiple clones representing the same regions). This allows for highly reliable detection of copy-number changes with little variation. However, the amount of material required for a two-slide microarray increases the cost of this platform. To reduce the cost of the array synthesis, we have created the SMRT re-array (SMRTr). The SMRTr array contains a more selective set of clones representing 83% of the original collection, eliminating unnecessary redundancy while maintaining tiling path coverage. As a result, the *27 000 clones can be spotted on to a single slide in duplicate, reducing the cost and time of analysis. These factors are important considerations in establishing whole genome array CGH for use in a clinical setting.
Recently, Bertone et al. (2004) constructed a series of 134 tiling arrays using 36-mer oligonucleotide probes representing the non-repetitive fraction of the human genome. This impressive work used *52 million probes with an average mapped spacing of 46 bp to assess the transcriptional activity throughout the genome, identifying over 10 000 novel expressed sequences. The feasibility of applying this array series to analyse genomic copynumber changes in tumour samples will probably be dependent on the adaptation of DNA ampli¢ca-tion techniques due to the amount of sample needed for using the entire array-set.
Complementary molecular cytogenetic approaches
Array CGH is a method for identifying copynumber alterations but it is not designed for tracking balanced translocations. Spectral karyotyping, also known as multiplex-fluorescence in-situ hybridization (FISH), or mFISH, employs chromosome-specific probes to detect gains, losses and rearrangements in a karyogram of colour-coded chromosomes (Garnis et al. 2004a ). However, microdeletions, inversions and duplications would escape detection by this method (Wang 2002) . The resolution limit of spectral karyotyping is reported to be about 3 Mb (Langer et al. 2004) . A variation of this method uses microdissected chromosomal regions, enabling reverse-FISH mapping against a normal metaphase chromosome spread (Wang 2002 , Langer et al. 2004 . In another variation, chimeric chromosomes isolated by flow sorting are used to paint targets on a genomic microarray (Fiegler et al. 2003b ). Digital karyotyping is another approach to detect SeGAs. This technique is modelled after serial analysis of gene expression or SAGE. Short nucleotide sequences (tags), adjacent to recognition sites of a restriction enzyme throughout the genome, are enumerated to deduce the relative abundance of tags in a Figure 5 . The probability of detecting genomic alterations with different array CGH profiling technologies. The probability of a genetic alteration not being detected due to being present in an area not covered by a microarray platform was calculated. For this analysis, we took into account the genomic mapping positions, the sizes of probes for each platform, the locations of telomeres and centromeres, and the criteria each platform uses to determine a region as altered (e.g. the number of clones needed to be altered to consider a region as changed). The number of possible genomic alterations of a given size was calculated for the human genome to determine the percent of possible alterations detectable by each platform. Not surprisingly, the probability of detecting a random alteration decreases for each array type as the size of the alteration decreases. Interestingly, the probability of detecting an alteration of a given size is not only dependent on the number of clones spotted on each array, but also on the size of the clones used to create the array. Larger clones like cDNAs and BACs (average size of 1.5 kb and 150 kb, respectively) have a greater chance of detecting microalterations, while arrays using smaller oligonucleotide probes (<70 bp), as represented by ROMA, have a lower likelihood of detecting alterations below 300 kbp. The SMRT array has the highest probability of detecting small alterations due to the contiguous set of clones used in its construction, with only a small number of interclone gaps which correspond to those in the human genome sequence. clone library, reflecting genomic copy number .
High-resolution view of tumour genomes
To illustrate the need for high-resolution genomic copy number analysis, examples of recent mantle cell lymphoma (MCL) genomic studies are considered. MCL is a B-cell malignancy characterized by t(11;14)(q13;q32 et al. (2004) used the whole-genome 32 433-clone tiling-path array to detect a mean of 35.6 alterations per MCL genome (range 21-57), and defined 35 regions of recurrent alteration. Of these recurrent regions, 37% have not been previously described and 26% were less than 1 Mb in size. The above studies of the MCL genome at increasing resolution show a striking, yet anticipated trend in the growing number of SeGAs detected in each sample: arrays with more comprehensive genomic coverage are able to resolve a greater number of alterations. Although the samples used in the de Leeuw et al. study were MCL lines that could potentially be subjected to culture artefacts, the detection of 35 alterations per sample remains unprecedented. Furthermore, many of the recurrent regions delineated were submegabase in size, harbouring only 1-2 candidate genes. For example, at tiling resolution, a 2.4-Mb loss at 8p21 initially identified by Kohlhammer et al. was further refined to 730 kb containing three candidate tumour suppressor genes including TNFRSF10B (tumour necrosis factor receptor superfamily, members 10B). Such regions may go undetected with low-resolution techniques. As with the MCL study, our experience using tiling-set arrays in profiling lung, head & neck, colorectal, breast and prostate tumours suggests that cancer genomes harbour multiple small segmental genomic alterations. These observations reinforce the need to analyse tumour genomes at a resolution far greater than conventional techniques offer. An important caveat that has gained much attention recently is the unexpected scale of copy-number polymorphisms in the human genome. Studies by Iafrate et al. (2004) and Sebat et al. (2004) have identi¢ed over 200 large-scale copy-number variations throughout the genome, ranging from about 100 kb to >2 Mb in size. As higher-resolution studies are undertaken, the contribution of polymorphisms to the number of 'alterations' detected will need to be addressed. The distinction between inherited polymorphisms and somatic changes can be achieved by careful study design and reference selection, for example, by comparing normal and tumour DNA from the same individuals or by deducing a catalogue of copy number polymorphisms in the human population. However, it may prove worthwhile to determine if a given polymorphism or set of polymorphisms play a role in certain cancer predispositions.
High-resolution analysis of tumour genomes is needed for the discovery of genes involved in the disease. This is evident for two main reasons. First, high-resolution array CGH has the capability to re¢ne known consensus regions of alterations. This is important as it allows researchers to narrow their focus to smaller areas of the genome. For example, trisomy 12 is often found in MCL. In their study, de Leeuw et al. (2004) did not see complete trisomy of this chromosome; however, they did discover six distinct recurrent regions of gain over the short and long arm of chromosome 12, one as small as 370 kb containing only two genes. This re¢nement greatly facilitates and expedites the functional validation of candidate cancer-related genes. Second, high-resolution analysis has a greater probability of detecting small novel alterations that may be important for the disease but may be missed by lower-resolution techniques ( Figure 5 ). As array-based CGH continues to increase in resolution, cancer genes will continue to become easier to discover. At least in principle, a major hurdle that may limit the feasibility of establishing these techniques for most research laboratories is the inability to manage the vast amounts of data generated. For the same reason, highresolution arrays may not be practical for clinical use. However, regions discovered using these arrays may be used to create smaller diagnostic arrays that will allow the power of array CGH to be combined with ease of use (discussed below).
Genetic changes associated with cancer progression
The advancements in array CGH technology have contributed to the study and understanding of underlying genetic changes that correspond to disease progression. Martinez-Climent et al. (2003) have used a 2400-clone array with a 1.4 Mb resolution to study follicular centre lymphoma (FCL) cell lines and paired biopsies from patients who have transformed from FCL to the more aggressive diffuse large B-cell lymphoma (DLBCL). The genomic profiles were then compared with their corresponding gene expression data for FCL to DLBCL transformation from another study (Lossos et al. 2002) . An increase in genomic complexity was observed in association with transformation. Though the expression of a number of genes positively correlated with the type of segmental genomic alteration in which they resided (e.g. overexpression in a gained region), the expression of a larger number of genes within the transformation-identified SeGAs remained unaltered. The heterogeneous mix of SeGAs and the complex correlation between genetic alterations and gene expression lead the authors to conclude that larger data sets will be needed to identify genetic events causal to FCL transformation.
Other studies have focused on using array CGH to describe the genetic events accompanying the progression of premalignant lesions to cancers. Weiss et al. (2003) have used a 1.4 Mb interval marker-based array to compare gastric hyperplastic polyps containing intraepithelial neoplasia (dysplasia) to gastric adenomas. The hyperplastic polyps contained numbers of SeGAs per sample comparable to the adenomas. However, both the polyps and adenomas had fewer SeGAs per sample when compared with gastric carcinoma pro¢les. Interestingly, though the polyps and adenomas contained di¡erent SeGAs from each other, the gastric carcinomas contained genetic aberrations common to both premalignant lesion types. These results support the idea that two di¡erent origins of gastric cancer exist, generating through either the hyperplastic polyp or the adenoma pathway.
A breast cancer case study by Nyante et al. (2004) used a 1.4 Mb interval array to examine the relationship between a lobular carcinoma in situ (LCIS) sample, a ductal carcinoma in situ (DCIS) sample, and an invasive lobular cancer (ILC) sample from a single patient. Under current breast cancer management protocols, the presence of LCIS is considered to be a risk factor for breast cancer, whereas DCIS is considered a lesion that leads to invasive cancer, resulting in a more aggressive treatment regimen. Yet, the study by Nyante et al. (2004) suggests that LCIS and ILC share a genomic signature distinct from the DCIS samples even though LCIS and ILC appear histopathologically di¡erent. The presence of this clonality suggests that LCIS can progress to an invasive cancer. However, further studies with a larger sample size are needed to substantiate these claims.
A study using a tiling-path array for the chromosome 1 short arm on preinvasive lung carcinoma in-situ samples shows very few recurrent changes on 1p in early lesions . However, the one recurrent lesion was 0.2 Mb in size and contained the developmental gene, WNT4. This led to the investigation of a number of genes involved in the WNT and Notch pathways that were recurrently observed in SeGAs in lung squamous cell carcinomas. Interestingly, a number of these genes were overexpressed in late-stage tumours, supporting the hypothesis that tumours may originate from dysregulated stem cells. Parallel studies on other chromosomes by the same group have demonstrated the value in examining preinvasive lesions as early genetic events may be masked by subsequent changes in invasive cancer (Garnis et al. 2004a ).
An important and well-known characteristic of most cancer cells is the increase in genetic instability during disease progression. Indeed, this is highlighted in the studies mentioned: all laterstage tumours had a greater average number of SeGAs per sample than their precursors. Though many of these secondary genetic changes may be responsible for disease maintenance and proliferation, the majority are not likely to contribute to pathogenesis and are probably a consequence of random events. This is suggested in the study by Martinez-Climent et al. (2003) , in which the majority of the genes within the identi¢ed SeGAs had unaltered expression levels. Discovering frequently altered regions may reveal important diseaserelated genes; however, these genes are not necessarily causal to tumour formation. Studying premalignant or precursor lesions helps to avoid these issues. The increased genomic stability of tumour precursors improves the likelihood that a SeGA discovered may be necessary for the disease. Furthermore, discovering localized regions that contain these genes might be easier, as they may not be 'masked' by the gross genetic alterations occurring at later stages. Clearly, the data generated by these precursor studies is valuable. This is even more evident when one considers the rarity of these lesions. For example, a practicing clinician may only encounter a lung carcinoma in situ once every few years (Stephen Lam, personal communication). As detection techniques improve and screening programmes are implemented, the chance to study these precious lesions will increase, which will assuredly generate a better understanding of cancer progression and aetiology.
Clinical translation
At this point, array CGH technology has been used primarily as a tool for discovering genetic alterations. Relating alterations to clinical features could yield markers predictive of disease behaviour. For example, the correlation of mantle cell lymphoma matrix CGH data with clinical course showed that 8p and 13q14 deletions conferred poor prognosis . In a recent report, Lichter and colleagues developed a chronic lymphocytic leukaemia array to demonstrate the potential in adapting this technology as an automated tool in clinical classification ).
The correlation of cytogenetic aberrations with disease outcome has already proven to be reliable and utilized in guiding treatment. Somatic mutations are stable unlike gene expression changes which may be transient. Detection of changes in tumour DNA, such as loss of heterozygosity, gene ampli¢cation and microsatellite instability, became useful markers associated with malignant development. Historically, technological developments such as £uorescence in-situ hybridization and comparative genomic hybridization greatly increased the resolution power of the cytogenetic approach with concomitant bene¢ts. Signi¢cantly, array CGH has the potential to improve this resolution by orders of magnitude at a reasonable cost and o¡ers the capacity to be high throughput. This is especially applicable to the analysis of solid tumours where in-vitro cell culture for karyotype analysis is di⁄cult. The major challenges in adapting this technology for a clinical setting are making the technology: (1) robust and simple to use which would require development in instrumentation and analytical software, and (2) price competitive with the current clinical cytogenetic techniques.
